Toggle navigation
Home
Search
Services
Blog
Contact
About
Phase I Clinical Trial Unit for Therapeutics Against Infectious Diseases: Evaluation of Therapeutics for MERS-CoV
Shumway, David
Dynport Vaccine Company, LLC, Frederick, MD, United States
Search 14 grants from David Shumway
Search grants from Dynport Vaccine Company, LLC
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Live-attenuated Rift Valley fever vaccines: comparative mechanisms of trans-placental transmission and vaccine efficacy for developing fetuses
Mitochondrial DNA: a target and effector of pulmonary epithelial cell injury
Oral Opioid Treatment and Psychiatric Comorbidity
Panic and Smoking Cessation
CAREER: Integrated Biosynthetic and Single-Molecule Approaches to Investigate Collective Motor Protein Dynamics
Recently added grants:
Anastrozole in Pulmonary Arterial Hypertension (AIPH2) - DCC
Biology of ?-linked glycosylceramides in the immune system
Genetics of Endocytic Trafficking in the Drosophila Eye
Estrogen signaling and energy metabolism in pulmonary arterial hypertension
Targeted depletion of programmed death-1 positive cells, a method that not only stops autoimmune attack but also preserves adaptive immunity
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research and Development Contracts (N01)
Project #
272201500005I-1-27200003-1
Application #
9430351
Study Section
Project Start
2016-08-23
Project End
2017-04-30
Budget Start
Budget End
Support Year
Fiscal Year
2017
Total Cost
Indirect Cost
Institution
Name
Dynport Vaccine Company, LLC
Department
Type
DUNS #
014130053
City
Frederick
State
MD
Country
United States
Zip Code
21702
Related projects
Show
10
25
50
100
entries
Processing...
Comments
Be the first to comment on David Shumway's grant
